Free Trial
→ My next big call (under $1) (From Crypto 101 Media) (Ad)tc pixel
NASDAQ:MIST

Milestone Pharmaceuticals Q3 2026 Earnings Date & Estimates

Milestone Pharmaceuticals logo
$0.78 +0.02 (+2.51%)
As of 12:03 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Milestone Pharmaceuticals is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. The conference call is scheduled for November 12, 2026 at 9:30 AM ET.

Research:ProfileEarnings HistoryForecast

Upcoming Earnings Announcement

Quarter
Q3 2026
Announcement Date
Time
Before Market Opens
Conference Call Date
Conference Call
9:30 AM ET
Google Calendar (opens in a new tab)Outlook (opens in a new tab)Yahoo Calendar (opens in a new tab)

What Analysts Expect from Milestone Pharmaceuticals in Q3 2026

Milestone Pharmaceuticals is expected to post earnings of -$0.20 per share on revenue of $1.14 million. In the same quarter a year earlier Milestone Pharmaceuticals reported -$0.12 per share. Milestone Pharmaceuticals last reported on August 12, 2026, posting -$0.21 per share and missing the -$0.1950 consensus estimate. Milestone Pharmaceuticals has beaten the consensus EPS estimate in 4 of its last 8 quarters.

Consensus Estimates

Consensus EPS
-$0.20
Expected Revenue
$1.14 million
Prior-Year EPS
-$0.12

Recent Track Record

Last Reported
Q2 2026
Last Quarter EPS
-$0.21 (Missed by -$0.0150)
Last Quarter Revenue
$0.56 million
EPS Beat Rate
4 of last 8 quarters

Prepare for the Q3 2026 Call

Milestone Pharmaceuticals Q3 2026 Earnings FAQ

Milestone Pharmaceuticals (NASDAQ:MIST) is estimated to report Q3 2026 earnings on Wednesday, November 11, 2026, before market opens. This date is estimated from past reporting schedules and may change once the company confirms it.

Milestone Pharmaceuticals' Q3 2026 earnings conference call is scheduled for Thursday, November 12, 2026 at 9:30 AM ET. MarketBeat streams the conference call audio and posts the transcript as soon as possible on the earnings announcement date.

Analysts expect Milestone Pharmaceuticals to post earnings of -$0.20 per share for Q3 2026.

The consensus revenue estimate for Milestone Pharmaceuticals is $1.14 million for Q3 2026.

Milestone Pharmaceuticals Earnings Headlines

Milestone Moves Etripamil AFib-RVR Program Forward With First European Patient; Stock Up
October 9, 2026  |  rttnews.comhttps://www.rttnews.com/3697912/milestone-moves-etripamil-afib-rvr-program-forward-with-first-european-patient-stock-up.aspx
Milestone Pharmaceuticals Enrolls First EU Patient in Phase 3 Etripamil Trial in Atrial Fibrillation
October 9, 2026  |  finance.yahoo.comhttps://finance.yahoo.com/healthcare/articles/milestone-pharmaceuticals-enrolls-first-eu-124351509.html
I have publicly predicted six major American crashes, before each one happened.
Dr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each warning issued before the crisis hit. Now the founder of Weiss Ratings, the only conflict-free rating agency in America, says he is watching a $3 trillion problem that could trigger a chain reaction across markets and banks.tc pixel
October 14 at 1:00 AM  |  Weiss Ratings (Ad)
Milestone Pharmaceuticals Announces First European Study Participant Enrolled in ReVeRA-301 Phase 3 Clinical Trial
October 9, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/10/09/3378055/0/en/milestone-pharmaceuticals-announces-first-european-study-participant-enrolled-in-revera-301-phase-3-clinical-trial.html
Milestone Enrolls First Canadian Patient In Phase 3 For Etripamil
September 27, 2026  |  rttnews.comhttps://www.rttnews.com/3694088/milestone-enrolls-first-canadian-patient-in-phase-3-for-etripamil.aspx
Milestone Pharmaceuticals Enrolls First Canadian Study Participant in ReVeRA-301 Phase 3 Pivotal Trial Evaluating Etripamil Nasal Spray for AFib-RVR
September 24, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/09/24/3368250/0/en/milestone-pharmaceuticals-enrolls-first-canadian-study-participant-in-revera-301-phase-3-pivotal-trial-evaluating-etripamil-nasal-spray-for-afib-rvr.html
See More Milestone Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Milestone Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Milestone Pharmaceuticals and other key companies, straight to your email.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals (NASDAQ:MIST) is a biopharmaceutical company focused on developing and commercializing therapies for cardiovascular conditions. The company’s lead product candidate is etripamil, a short-acting calcium channel blocker formulated as a nasal spray and designed for rapid, patient-administered treatment.

Etripamil has been studied primarily for paroxysmal supraventricular tachycardia (PSVT), a condition characterized by episodes of abnormally rapid heart rate. The product is intended to provide patients with an option for treating episodes outside of a hospital or clinic, potentially reducing the need for emergency medical intervention. Milestone has also evaluated etripamil in other cardiovascular settings, including the management of certain blood-pressure-related conditions.

Founded in 2013, Milestone Pharmaceuticals conducts its research and development activities in North America and has advanced etripamil through clinical development programs intended to support regulatory review. The company is headquartered in Montreal, Quebec, and has been led by President and Chief Executive Officer Joseph Oliveto.

View Milestone Pharmaceuticals Profile
Earnings Tools